强直性脊柱炎诊断和治疗研究现状  

Research Status of Diagnosis and Treatment of Ankylosing Spondylitis

作　　者：云雪 郭华 

机构地区：[1]延安大学医学院,陕西 延安 [2]西安市第五医院脊柱外科,陕西 西安

出　　处：《临床个性化医学》2024年第4期2643-2652,共10页Journal of Clinical Personalized Medicine

基　　金：陕西省西安市科技计划项目(22YXYJ0004);陕西省西安市科技计划项目(XAYC220010)。

摘　　要：强直性脊柱炎是一种慢性自身免疫性疾病,主要累计中轴骨骼和骶髂关节。以前诊断强直性脊柱炎依靠X线,但是由于其只能确诊晚期患者,因此,国际脊柱关节炎协会(ASAS)重新制定了新的分类标准,并且将MRI作为该病的主要诊断工具。JAK-STAT通路的发现推动了针对JAK的抗体的产生,并在治疗AS中显示出与TNF抑制剂具有相似的效果。而间充质干细胞在治疗其他疾病时,已被多项研究证实其安全性和有效性,但其在治疗AS需要进一步研究。本文就强直性脊柱炎的早期诊断、治疗方法的研究进展作一综述。Ankylosing spondylitis (AS) is a chronic autoimmune disease that primarily affects the axial skeleton and sacroiliac joints. Previously, the diagnosis of ankylosing spondylitis relied on X-rays, but since they can only confirm cases in the later stages of the disease, the Assessment of Spondylo Arthritis International Society (ASAS) has revised the classification criteria and designated MRI as the primary diagnostic tool for this condition. The identification of the JAK-STAT signaling pathway has facilitated the development of antibodies directed against JAK, demonstrating therapeutic effects comparable to those of TNF inhibitors in the management of ankylosing spondylitis. Multiple studies have established the safety and efficacy of mesenchymal stem cells in the treatment of various diseases;however, additional research is warranted to explore their application in the management of ankylosing spondylitis. This article presents a comprehensive review of the advancements in research pertaining to the early diagnosis and treatment modalities of ankylosing spondylitis.

关 键 词：强直性脊柱炎 脊柱关节炎 TNF抑制剂 JAK抑制剂 间充质干细胞 

分 类 号：R59[医药卫生—内科学]